SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 215.75 |
| Enterprise Value ($M) | 143.12 |
| Book Value ($M) | 257.29 |
| Book Value / Share | 4.77 |
| Price / Book | 0.84 |
| NCAV ($M) | 245.77 |
| NCAV / Share | 4.56 |
| Price / NCAV | 0.88 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.07 |
| Return on Assets (ROA) | -0.07 |
| Return on Equity (ROE) | -0.08 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 18.44 |
| Current Ratio | 18.44 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 267.49 |
| Assets | 279.01 |
| Liabilities | 21.72 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | BlackRock, Inc. | 10.30 | -2.30 | |
| 13G/A | Rtw Investments, Lp | 0.00 | -100.00 | |
| 13G/A | Suvretta Capital Management, Llc | 2.20 | -78.57 | |
| 13G/A | Vanguard Group Inc | 5.24 | 0.00 | |
| 13G/A | Fmr Llc | 2.76 | -69.67 | |
| 13G | TCG Crossover GP II, LLC | 9.40 | ||
| 13G/A | Ra Capital Management, L.p. | 19.30 | 84.50 | |
| 13G/A | Third Rock Ventures III, L.P. | 3.80 | 0.00 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 2.44 | -56.59 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 60,430 | 330,291 | 18.30 | |
| 34,814 | 311,646 | 11.17 | |
| 42,300 | 424,108 | 9.97 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FBLG – FibroBiologics, Inc. | FHTX – Foghorn Therapeutics Inc. |
| FOLD – Amicus Therapeutics, Inc. | GANX – Gain Therapeutics, Inc. |
| GHRS – GH Research PLC |
Financial data and stock pages provided by
Fintel.io